Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin- 2-receptor monoclonal antibody

Transplantation

Volumn 67, Issue 2, 1999, Pages 276-284

  Kahan, Barry D ^a   Rajagopalan, P R ^b   Hall, Michael ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; LYMPHOCYTE; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; CAUSE OF DEATH; CREATININE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 0033608073     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199901270-00016     Document Type: Article

References (37)

1. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169.
2. Leonard WJ, Depper JM, Crabtree GR, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 1984; 311: 626.
3. Hatakeyama M, Tsudo M, Minamoto S, et al. Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNAs. Science 1989; 244: 551.
4. Gruber SA, Chan GLC, Canafax DM, Matas AJ. Immunosuppression in renal transplantation. II. Corticosteroids, antilymphocyte globulin, and OKT3. Clin Transplant 1991; 5: 219.
5. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358.
6. Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB. Therapy with monoclonal antibody to interleukin 2 receptor spares T suppressor cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 1989; 83: 2624.
7. Reed MH, Shapiro ME, Strom TB, et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 1989; 47: 55.
8. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
9. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford I EL, Ramos EL. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
10. Iberer F, Tscheliessnigg KH, Freigassner M, et al. Clinical experience with a monoclonal interleukin-2 receptor antibody (BTA 563) for rejection therapy after orthotopic heart transplantation. Transplant Proc 1994; 26: 3237.
11. Reding R, Vraux H, de Ville de Goyet J, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation: a randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1. Transplantation 1993; 55.
12. Neuhaus P, Bechstein WO, Blumhardt G, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993; 55: 1320.
13. Soulillou JP, Peyronnet P, Le Mauff B, et al. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet 1987; i: 1339.
14. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
15. Amlot P. The clinical and experimental use of monoclonal antibodies to the IL-2 receptor. In: Chatenoud L, ed. Monoclonal antibodies in transplantation. Austin, TX: RC Landes Co; 1995.
16. Kovarik J, Wolf P, Cisterne JM, et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997; 64: 1701.
17. Kovarik J, Wolf P, Durand D, et al. Pharmacokinetics of Simulect in recipients of cadaver kidney transplants (Abstract]. The American Society of Transplant Physicians 15th Annual Scientific Meeting, 1997.
18. Kovarik JM, Rawlings E, Sweny P, et al. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation. Transplant Proc 1996; 28: 913.
19. Heinrich G, Gram G, Kocher HP, et al. Characterization of a human T cell specific chimeric antibody (CD7) with human constant and mouse variable regions. J Immunol 1989; 143: 3589.
20. CPMP Working Party on Safety of Medicinal Products. EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990; 67: 361.
21. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Ferney-Voltaire, France: World Medical Association; 1989.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
23. 1/2). Transplantation 1994; 57: 857.
24. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Lancet 1995; 345: 1321.
25. Sollinger HW, U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
26. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
27. Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; 29: 48.
28. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
29. Nashan B, Moore R, Amlot P, Schmidt A-G. Abeywickrama K, Soulillou J-P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
30. Batiuk TD, Bennett WM, Norman DJ. Cytokine nephropathy during antilymphocyte therapy. Transplant Proc 1993; 25 (2) (Suppl 1): 27.
31. First MR, Schroeder TJ, Hariharan S. OKT3-induced cytokine-release syndrome: renaleffects (cytokine nephropathy). Transplant Proc 1993; 25 (2) (Suppl 1): 25.
32. Kelly PA, Burckart GJ, Venkataramanan R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995; 52: 1521.
33. Desehler DG, Osorio R, Ascher NL, Lee KC. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. Arch Otolaryngol Head Neck Surg 1995; 121: 1037.
34. Furtli S, Neu A, Colombani P, Plotnik L, Turner ME, Fivush B. Diabetes as a complication of tacrolimus (FK 506) in pediatric liver transplant patients. Pediatr Nephrol 1996; 10: 64.
35. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin-2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029.
36. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
37. Nashan B, Schlitt HJ, Schwinzer R. et al. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 1996; 61: 546.